Table 3. Multivariable Cox Regression Analyses for All‐Cause Mortality, Cardiovascular Mortality, and MACE at 5 Years
ModelAll‐Cause MortalityCardiovascular MortalityMACE
HR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P Value
Log2‐NT‐IGFBP‐4
All patients (n=656)
Univariable3.33 (2.69–4.13)<0.0014.36 (3.25–5.86)<0.0012.71 (2.22–3.30)<0.001
Model 12.13 (1.53–2.97)<0.0012.54 (1.59–4.07)<0.0011.97 (1.48–2.61)<0.001
Model 22.19 (1.55–3.10)<0.0012.70 (1.65–4.41)<0.0011.93 (1.45–2.58)<0.001
Subgroup with LVEF (n=344)
Univariable2.17 (1.47–3.21)<0.0014.09 (2.08–8.03)<0.0012.35 (1.74–3.18)<0.001
Model 11.75 (1.05–3.10)0.0312.62 (0.97–7.05)0.0571.66 (1.09–2.51)0.017
Univariable plus LVEF2.12 (1.42–3.15)<0.0013.85 (1.93–7.67)<0.0012.13 (1.57–2.89)<0.001
Model 1 plus LVEF1.72 (1.02–3.09)0.0422.63 (1.01–7.05)0.0471.59 (1.03–2.45)0.035
Log2‐CT‐IGFBP‐4
All patients (n=656)
Univariable2.78 (2.27–3.40)<0.0013.69 (2.78–4.89)<0.0012.38 (1.98–2.86)<0.001
Model 11.74 (1.33–2.29)<0.0012.07 (1.41–3.04)<0.0011.70 (1.35–2.15)<0.001
Model 21.78 (1.34–2.37)<0.0012.13 (1.43–3.16)<0.0011.70 (1.34–2.16)<0.001
Subgroup with LVEF (n=344)
Univariable2.11 (1.49–2.97)<0.0014.29 (2.23–8.25)<0.0012.29 (1.73–3.03)<0.001
Model 11.79 (1.11–2.89)0.0163.63 (1.32–9.99)0.0121.65 (1.16–2.35)0.006
Univariable plus LVEF2.06 (1.46–2.92)<0.0014.02 (2.07–7.82)<0.0012.12 (1.60–2.79)<0.001
Model 1 plus LVEF1.78 (1.10–2.87)0.0193.62 (1.31–9.95)0.0131.60 (1.11–2.29)0.012
  • Model 1: age, sex, estimated glomerular filtration rate, hypertension, high‐density lipoprotein, total cholesterol, systolic blood pressure, hemoglobin, current smoking, diabetes, previous acute myocardial infarction, multivessel coronary artery disease, complex lesion, C‐reactive protein, and peak troponin I. Model 2: model 1 plus body mass index, hypercholesterolemia, low‐density lipoprotein, triglyceride, symptom‐to‐balloon time, and use of glycoprotein IIb/IIIa inhibitor. Separate analyses were performed on the subgroup of patients with LVEF measurements (n=344). Results are reported as HR and 95% CI. One‐unit increase in NT‐ or CT‐IGFBP‐4 on the log2‐scale corresponds to a doubling in NT‐ or CT‐IGFBP‐4, respectively. CT indicates C‐terminal; HR, hazard ratio; IGFBP‐4, insulin‐like growth factor binding protein 4; LVEF, Left ventricular ejection fraction; MACE, major adverse cardiac event; NT, N‐terminal.